Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Mattheus · SciRah

Researcher profile · Semantic Scholar

M. Mattheus

Share profile

M. Mattheus — researcher profile on SciRah

h-index: 31
Works: 108
Citations: 13K

Most-cited papers

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
B. Zinman, C. Wanner, J. Lachin, D. Fitchett +8 more
2015New England Journal of Medicine6,082 citations Open access
Semantic Scholar
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
C. Wanner, S. Inzucchi, J. Lachin, D. Fitchett +6 more
2016New England Journal of Medicine3,098 citations Open access
Semantic Scholar
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock, S. Kahn, O. Johansen, B. Zinman +11 more
2019Journal of the American Medical Association (JAMA)532 citations Open access
Semantic Scholar
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
C. Wanner, J. Lachin, S. Inzucchi, D. Fitchett +6 more
2018Circulation386 citations Open access
Semantic Scholar
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
D. Cherney, B. Zinman, S. Inzucchi, A. Koitka-Weber +3 more
2017The Lancet Diabetes and Endocrinology340 citations
Semantic Scholar
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
N. Marx, J. Rosenstock, S. Kahn, B. Zinman +9 more
2015Diabetes & vascular disease research224 citations Open access
Semantic Scholar
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
B. Kraus, M. Weir, G. Bakris, M. Mattheus +9 more
2020Kidney International199 citations Open access
Semantic Scholar
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
C. Wanner, H. Heerspink, B. Zinman, S. Inzucchi +7 more
2018Journal of the American Society of Nephrology173 citations Open access
Semantic Scholar
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®.
K. Kaku, Jisoo Lee, M. Mattheus, S. Kaspers +2 more
2017Circulation Journal119 citations Open access
Semantic Scholar
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
B. Zinman, S. Inzucchi, J. Lachin, C. Wanner +8 more
2017Stroke118 citations Open access
Semantic Scholar
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
S. Macha, M. Mattheus, A. Halabi, Sabine Pinnetti +2 more
2014Diabetes, obesity and metabolism117 citations
Semantic Scholar
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
M. Böhm, J. Slawik, M. Brueckmann, M. Mattheus +9 more
2019European Journal of Heart Failure98 citations Open access
Semantic Scholar
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
J. Jordan, J. Tank, K. Heusser, T. Heise +7 more
2017Journal of the American Society of Hypertension : JASH88 citations
Semantic Scholar
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
T. Heise, J. Jordan, C. Wanner, M. Heer +5 more
2016Clinical Therapeutics85 citations
Semantic Scholar
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
J. Rosenstock, V. Perkovic, J. Alexander, M. Cooper +13 more
2018Cardiovascular Diabetology80 citations Open access
Semantic Scholar
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
A. F. Hernandez, J. Udell, W. Jones, Stefan D. Anker +38 more
2024Circulation76 citations Open access
Semantic Scholar
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
S. Macha, P. Rose, M. Mattheus, R. Cinca +3 more
2014Diabetes, obesity and metabolism70 citations
Semantic Scholar
A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
C. Friedrich, Katrin Metzmann, P. Rose, M. Mattheus +2 more
2013Clinical Therapeutics68 citations
Semantic Scholar
Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
Simke W. Waijer, D. Xie, S. Inzucchi, B. Zinman +6 more
2020Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease66 citations Open access
Semantic Scholar
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
D. McGuire, B. Zinman, S. Inzucchi, C. Wanner +12 more
2020The Lancet Diabetes and Endocrinology64 citations
Semantic Scholar
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
J. Ferreira, S. Inzucchi, M. Mattheus, T. Meinicke +3 more
2021Diabetes, obesity and metabolism61 citations Open access
Semantic Scholar
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.
T. Heise, J. Jordan, C. Wanner, M. Heer +5 more
2016Clinical Therapeutics57 citations
Semantic Scholar
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
C. Wanner, M. Nangaku, B. Kraus, B. Zinman +6 more
2024Nephrology, Dialysis and Transplantation48 citations Open access
Semantic Scholar
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
S. Inzucchi, K. Khunti, D. Fitchett, C. Wanner +4 more
2020Journal of Clinical Endocrinology and Metabolism38 citations Open access
Semantic Scholar
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
D. Fitchett, S. Inzucchi, J. Lachin, C. Wanner +7 more
2018Journal of the American College of Cardiology37 citations Open access
Semantic Scholar
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced
F. Zannad, J. Ferreira, J. Gregson, B. J. Kraus +8 more
2022European Journal of Heart Failure36 citations
Semantic Scholar
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
D. Fitchett, S. Inzucchi, C. Wanner, M. Mattheus +4 more
2019European Heart Journal36 citations Open access
Semantic Scholar
Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers
S. Macha, P. Rose, M. Mattheus, Sabine Pinnetti +1 more
2013Diabetes, obesity and metabolism31 citations
Semantic Scholar
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial
M. Espeland, R. Pratley, J. Rosenstock, T. Kadowaki +9 more
2020Diabetes, obesity and metabolism30 citations Open access
Semantic Scholar
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
G. Biessels, J. Janssen, Esther van den Berg, B. Zinman +3 more
2018BMC Neurology26 citations Open access
Semantic Scholar
Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
T. Heise, M. Mattheus, H. Woerle, Uli C. Broedl +1 more
2015Clinical Therapeutics25 citations
Semantic Scholar
HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy
J. Janssen, Esther van den Berg, B. Zinman, M. Espeland +4 more
2018Diabetes Care21 citations Open access
Semantic Scholar
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Preserved
T. Rastogi, J. Ferreira, J. Butler, B. Kraus +8 more
2024European Journal of Heart Failure20 citations Open access
Semantic Scholar
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
S. Macha, M. Mattheus, Sabine Pinnetti, Uli C. Broedl +1 more
2015Clinical Therapeutics19 citations
Semantic Scholar
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
M. Vaduganathan, S. Inzucchi, N. Sattar, D. Fitchett +8 more
2021Diabetes, obesity and metabolism18 citations Open access
Semantic Scholar
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
P. Ruggenenti, B. Kraus, S. Inzucchi, B. Zinman +6 more
2021EClinicalMedicine18 citations Open access
Semantic Scholar
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
K. Kaku, C. Wanner, S. Anker, S. Pocock +3 more
2021Diabetes, obesity and metabolism18 citations Open access
Semantic Scholar
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease
Abhinav Sharma, S. Inzucchi, J. Testani, A. Ofstad +6 more
2023ESC Heart Failure17 citations Open access
Semantic Scholar
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
S. Verma, Lawrence A Leiter, B. Zinman, Abhinav K. Sharma +7 more
2021ESC Heart Failure17 citations Open access
Semantic Scholar
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial
T. Kadowaki, Guang Wang, J. Rosenstock, D. Yabe +8 more
2020Diabetology International13 citations Open access
Semantic Scholar
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin
Nikolaus Marx, A. Kolkailah, J. Rosenstock, O. Johansen +10 more
2024JAMA cardiology12 citations Open access
Semantic Scholar
Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c
D. Fitchett, J. McKnight, Jisoo Lee, J. George +3 more
2017Diabetologie und Stoffwechsel12 citations
Semantic Scholar
EMPAGLIFLOZIN (EMPA) REDUCES HEART FAILURE OUTCOMES IRRESPECTIVE OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C CONTROL
D. Fitchett, J. Lee, J. George, M. Mattheus +1 more
201710 citations
Semantic Scholar
Abstract 13520: Empagliflozin Reduces Markers of Arterial Stiffness, Vascular Resistance and Cardiac Workload in EMPA-REG OUTCOME
R. Chilton, L. Gullestad, D. Fitchett, S. Inzucchi +3 more
2016Circulation9 citations
Semantic Scholar
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Priyadarshini Balasubramanian, W. Kernan, K. Sheth, A. Ofstad +6 more
2023Stroke8 citations Open access
Semantic Scholar
Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet .
S. Glund, M. Mattheus, F. Runge, P. Rose +1 more
2017International journal of clinical pharmacology and therapeutics8 citations
Semantic Scholar
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
J. Davidson, Rosemarie Lajara, R. Aguilar, M. Mattheus +2 more
2014BMJ Open Diabetes Research & Care7 citations Open access
Semantic Scholar
Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial
H. Bays, P. Gao, Birgit Völker, M. Mattheus +2 more
2013International Journal of Hypertension7 citations Open access
Semantic Scholar
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome
Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, D. Fitchett +6 more
2023American Journal of Preventive Cardiology6 citations Open access
Semantic Scholar
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.
B. Krämer, S. Hauske, R. Chilton, Johannes F. E. Mann +5 more
2023Journal of diabetes and its complications6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Wanner×26
Invite
C. Wanner — researcher profile on SciRah
B. Zinman×25
Invite
B. Zinman — researcher profile on SciRah
S. Inzucchi×22
Invite
S. Inzucchi — researcher profile on SciRah
H. Woerle×20
Invite
H. Woerle — researcher profile on SciRah

×16

Invite

D. Fitchett — researcher profile on SciRah

O. Johansen×14

Invite

O. Johansen — researcher profile on SciRah

Uli C. Broedl×14

Invite

Uli C. Broedl — researcher profile on SciRah

Invite

J. George — researcher profile on SciRah

M. von Eynatten×10

Invite

M. von Eynatten — researcher profile on SciRah

Invite

S. Macha — researcher profile on SciRah

Invite

N. Marx — researcher profile on SciRah

Invite

A. Ofstad — researcher profile on SciRah